RxDoctor Payments Data

Valery Effoe, MD

Interventional Cardiology · Lagrange, GANPI 1962865436

Payments from drug & device makers

$7,093in general payments, 2019–2025

Across 84 payments — averaging $84.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Boston Scientific$1K
  • Penumbra, Inc.$1K
  • Shockwave Medical, Inc$269
  • Cardiovascular Systems Inc.$172
  • W. L. Gore & Associates, Inc.$169
  • plus $987 from 20 others

What the payments were for

  • Travel & lodging$3,03543%
  • Food & beverage$3,30647%
  • Education$75111%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,093 in reported general payments places this provider in the 40th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$84,865
Medicare patients
626
Services billed
1,427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban95$67,429
XareltoRivaroxaban19$19,574
FarxigaDapagliflozin Propanediol26$14,568
JardianceEmpagliflozin11$6,508
Metoprolol Succinate98$751
Atorvastatin Calcium168$686
Ranolazine ErRanolazine15$601
Carvedilol84$563
ClopidogrelClopidogrel Bisulfate72$399
Losartan Potassium33$358
Lisinopril90$354
Hydralazine Hcl37$295
Cilostazol26$293
Nifedipine ErNifedipine23$250
Torsemide25$245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$53$67,42995 claims
AstraZenecaFarxiga$110$14,56826 claims
Boehringer IngelheimJardiance$71$6,50811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Lagrange

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →